Hemab Therapeutics Holdings Inc (COAG) Price Prediction & ForecastCOAGHemab Therapeutics Holdings Inc

Alphio's COAG stock price prediction model matches the current Hemab Therapeutics Holdings Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $35.37 (+2.82%). The 1-week path is $34.06 (-0.98%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Hemab Therapeutics (COAG) is a good buy right now due to its current price of $34.40, which is significantly below the analyst consensus target mean of $62.42, suggesting a potential upside of 105.68%. Additionally, the stock has shown a strong year-to-date change of +91.11%, indicating positive momentum. However, the main risk is the negative earnings per share (EPS) of -1.00 reported in Q2 2026, which reflects ongoing financial challenges.

Hemab Therapeutics Holdings Inc (COAG) last closed at $34.4, losing -1.19%. These facts feed the 1-day and 1-week COAG price prediction above.